Imviva Biotech is cleared to launch a basket Phase 1b trial testing its investigational off-the-shelf CAR T-cell therapy CTA313 in progressive multiple sclerosis (MS) and other B-cell-mediated autoimmune diseases. The announcement follows the clearance of the company’s investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). Trial to span 3 autoimmune […]

The post FDA clears CTA313 trial for progressive MS, autoimmune diseases appeared first on Multiple Sclerosis News Today.

Source: multiplesclerosisnewstoday.com